To investigate effects of beta blocker (BB; timolol or betaxolol), latanoprost, and latanoprost-timolol combination (LTC) drugs on corneal endothelial cell density (ECD) and central corneal thickness (CCT) in primary open-angle glaucoma (POAG) patients. Sixty-one patients in BB group, 64 patients in latanoprost group, 59 patients in LTC group, and 58 healthy cases in control group were included. Intraocular pressures (IOP), ECDs, and CCTs of groups were recorded at initial (pre-treatment) period, first and third years after treatment, and comparisons were done. In groups, changes of ECDs according to time were not significant (p > 0.05). In BB and control groups, changes of CCTs according to time were not significant (p > 0.05). In latanoprost and LTC groups, CCTs in both first and third years were significantly thinner than initial CCTs (p = 0.039 for latanoprost, p = 0.041 for LTC at first year; p = 0.018 for latanoprost, p = 0.032 for LTC at third year). In latanoprost and LTC groups, CCTs of patients using drugs for 1 year were similar to those of patients using drugs for 3 years (p > 0.05). In our study, uses of BB, latanoprost or LTC did not affect ECD. BB drugs had no effect on CCT. Although latanoprost and LTC appeared to reduce CCT at 3-year follow-up from the statistical point of view, this 8–10 μm difference in CCT was not clinically significant.
KonstasAGMocanMCKatsanosA, et al. Latanoprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Pharmacother2013; 14(13): 1815–1827.
2.
HoyngPFVan BeekLM. Pharmacological therapy for glaucoma, a review. Drugs2000; 59: 411–434.
3.
LeskeMCHeijlAHymanL, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology2007; 114: 1965–1972.
4.
European Glaucoma Society. Terminology and guidelines for glaucoma. 5th ed.Savona: PubliComm; 2020.
5.
YuZ-YWuLQuB. Changes in corneal endothelial cell density in patients with primary open-angle glaucoma. World J Clin Cases2019; 7(15): 1978–1985.
6.
LuoYLiJJinY. Changes of corneal endothelium in patients with primary glaucoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao2000; 22: 356–359.
7.
BafaMGeorgopoulosGMihasC, et al. The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes. Acta Ophthalmol2011; 89(5): 448–451.
8.
WierzbowskaJŁagockaASiemiatkowskaA, et al. The impact of common classes of topical antiglaucoma medications on central corneal thickness—own observations. Klin Oczna2009; 111(10–12): 323–326.
9.
ViswanathanDGoldbergIGrahamSL. Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clin Exp Ophthalmol2013; 41(4): 348–354.
10.
MillsRPBudenzDLLeePP, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol2006; 141(1): 24–30.
BlandJMAltmanDG. Measurement error and correlation coefficients. BMJ1996; 313(7048): 41–42.
13.
European glaucoma society terminology and guidelines for glaucoma. 4th ed - chapter 3: treatment principles and options supported by the EGS foundation: part 1: foreword; introduction; glossary; chapter 3 treatment principles and options. Br J Ophthalmol2017; 101(6): 130–195.
14.
BaratzKHNauCBWinterEJ, et al. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea2006; 25: 1046–1052.
15.
LassJHErikssonGLOsterlingL, et al. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology2001; 108(2): 264–271.
16.
NakanoTInoueRKimuraT, et al. Effects of brinzolamide, a topical carbonic anhydrase inhibitor, on corneal endothelial cells. Adv Ther2016; 33(8): 1452–1459.
17.
KwonJWRandGMChoKJ, et al. Association between corneal endothelial cell density and topical glaucoma medication use in an eye bank donor population. Cornea2016; 35: 1533–1536.
18.
Correa-PérezMELópez-MiguelAMiranda-AntaS, et al. Precision of high definition spectral-domain optical coherence tomography for measuring central corneal thickness. Invest Ophthalmol Vis Sci2012; 53(4): 1752–1757.
19.
VollmerLSowkaJPizzimentiJ, et al. Central corneal thickness measurements obtained with anterior segment spectral domain optical coherence tomography compared to ultrasound pachymetry in healthy subjects. Optometry2012; 83(5): 167–172.
20.
LiYTangMZhangX, et al. Pachymetric mapping with fourier-domain optical coherence tomography. J Cataract Refract Surg2010; 36(5): 826–831.
21.
PrakashGAgarwalAJacobS, et al. Comparison of fourier-domain and time-domain optical coherence tomography for assessment of corneal thickness and intersession repeatability. Am J Ophthalmol2009; 148: 282–290.
22.
MansooriTBalakrishnaN. Intrasession repeatability of pachymetry measurements with RTVue XR 100 optical coherence tomography in normal cornea. Saudi J Ophthalmol2017; 31(2): 65–68.
23.
NamSMImCYLeeHK, et al. Accuracy of RTVue optical coherence tomography, pentacam, and ultrasonic pachymetry for the measurement of central corneal thickness. Ophthalmology2010; 117: 2096–2103.
24.
HuangJYPekmezciMYapleeS, et al. Intra-examiner repeatability and agreement of corneal pachymetry map measurement by time-domain and fourier-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2010; 248(11): 1647–1656.
25.
McGrawKOWongSP. Forming inferences about some intraclass correlation coefficients. Psychol Methods1996; 1(1): 30–46.
26.
TsikripisPPapaconstantinouDKoutsandreaC, et al. The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes. Drug Des Devel Ther2013; 7: 1149–1156.
27.
GruebMRohrbachJM. Effect of timolol on central corneal thickness. Eur J Ophthalmol2013; 23(6): 784–788.
28.
GruebMBartz-SchmidtKURohrbachJM. Adrenergic regulation of cAMP/protein kinase a pathway in corneal epithelium and endothelium. Ophthalmic Res2008; 40(6): 322–328.
29.
SchremsWASchrems-HoeslLMMardinCY, et al. The effect of long-term antiglaucomatous drug administration on central corneal thickness. J Glaucoma2016; 25(3): 274–280.
30.
WuKYWangHZHongSJ. Effect of latanoprost on cultured procine corneal stromal cells. Curr Eye Res2005; 30: 871–879.
31.
StefanCDumitricaDMTebeanuE, et al. Prostaglandin analogues and central corneal thickness. Oftalmologica2007; 51(4): 95–99.
32.
SenENalcaciogluPYaziciA, et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma2008; 17(5): 398–402.
33.
KocabeyogluSMocanMCIrkecM. Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues. Indian J Ophthalmol2015; 63(1): 15–19.
34.
HatanakaMVessaniRMEliasIR, et al. The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther2009; 25(1): 51–53.
35.
ZhongYShenXYuJ, et al. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea2011; 30(8): 861–864.
36.
MaruyamaYMoriKIkedaY, et al. Effects of long-term topical prostaglandin therapy on central corneal thickness. J Ocul Pharmacol Ther2014; 30(5): 440–444.
37.
YouJYChoBJ. Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma. J Ocul Pharmacol Ther2013; 29(3): 335–338.
38.
LeeHChoBJ. Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results. J Ocul Pharmacol Ther2015; 31(3): 152–155.
39.
SagaraTGatonDDLindseyJD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol1999; 117(6): 794–801.
40.
ViestenzAMartusPSchlötzer-SchrehardtU, et al. Impact of prostaglandin-F (2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness—a cross-sectional study on 403 eyes. Klin Monbl Augenheilkd2004; 221(9): 753–756.
41.
LiuYYanaiRLuY, et al. Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma2006; 15: 255–259.
42.
ShenJWShanMPengYY, et al. Cytotoxic effect of latanoprost on human corneal stromal cells in vitro and its possible mechanisms. Curr Eye Res2017; 42: 534–541.
43.
BrewKDinakarpandianDNagaseH. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta2000; 1477: 267–283.
44.
AnthonyTLLindseyJDWeinrebRN. Latanoprost’s effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci2002; 43: 3705–3711.
45.
OhDJMartinJLWilliamsAJ, et al. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci2006; 47: 3887–3895.
46.
AghaianEChoeJELinS, et al. Central corneal thickness of caucasians, chinese, hispanics, filipinos, african americans, and japanese in a glaucoma clinic. Ophthalmology2004; 111: 2211–2219.
47.
ShimmyoMRossAJMoyA, et al. Intraocular pressure, goldmann applanation tension, corneal thickness, and corneal curvature in caucasians, asians, hispanics, and african americans. Am J Ophthalmol2003; 136: 603–613.
48.
ShahS. Accurate intraocular pressure measurement-the myth of modern ophthalmology?Ophthalmology2000; 107(10): 1805–1807.
49.
KohlhaasMBoehmAGSpoerlE, et al. Effect of central corneal thickness, corneal curvature, and axial length on applanation tonometry. Arch Ophthalmol2006; 124(4): 471–476.
50.
BelovayGWGoldbergI. The thick and thin of the central corneal thickness in glaucoma. Eye (Lond)2018; 32(5): 915–923.
